Phosphodiesterase type 5 (PDE5) inhibitors are first-line therapy for pulmonary arterial hypertension (PAH) and erectile dysfunction. As a continuing work to improve the terminal half-lives and oral bioavailabilities of our previously reported 4(3H)-pyrimidones, a pharmacokineticsdriven optimization focusing on the terminal substituent is described. Two major congeneric series of 4(3H)-pyrimidones, the aminosulfonylphenylpyrimidones and acylaminophenylpyrimidones, were designed, synthesized, and pharmacologically assessed in vitro and in vivo. Among them, compound 15 (TPN171) with subnanomolar potency for PDE5 and good selectivity over PDE6 was finally recognized as a potential drug candidate, and its pharmacokinetic profiles in rats and dogs are significantly improved compared to the starting compound (3). Moreover, TPN171 was proven to exert a longer lasting effect than sildenafil in animal models, providing a foundation for a once-daily oral administration for its clinical use. TPN171 is currently being investigated in a phase II clinical trial for the treatment of PAH.
A novel
synthetic route for making (−)-CBD and its derivatives
bearing various C4′-side chains is developed by a late-stage
diversification method. Starting from commercially available phloroglucinol,
the key intermediate (−)-CBD-2OPiv-OTf is efficiently and regioselectively
prepared and further undergoes Negishi cross-coupling to furnish (−)-CBD.
This approach allowed an efficient synthesis of (−)-CBD in
a five-step total 52% yield on a 10 g scale. Furthermore, diversification
on the C4′-side chain with this method can be realized in a
wide range.
A one-pot process
for preparing molnupiravir from cytidine was
developed. The advantages of this synthesis were as follows: (1) The
presence of N,N-dimethylformamide
dimethyl acetal (DMF-DMA) facilitated the selective protection of
2′,3′-dihydroxyls and amino of cytidine, which eliminated
the negative impact of these groups on the following isobutyrylation
at 5′-hydroxyl. (2) Degradations of the product in the deprotection
stage were avoided since a mild condition was used. (3) The achievement
of deprotection and hydroxyamination in one single step improved the
synthetic efficiency. (4) Molnupiravir with high purity (purity up
to 99.7% analyzed by high-performance liquid chromatography (HPLC))
was obtained in a yield of 63% through crystallization.
The
development of an industrially scalable synthetic route for
5,7-dichlorotetrahydroisoquinoline-6-carboxylic acid (1), a key starting material for lifitegrast, is described. This route
includes the following features: (1) tetrahydroisoquinoline 19 was prepared in three steps from readily commercially available
3,5-dichlorobenzoyl chloride and 2-aminoethanol in a high total yield
of 76%; (2) formaldehyde instead of triphenylmethyl chloride was employed
in the protection of the secondary amine, resulting in much higher
atom economy; (3) the target compound 1 was produced
in an overall yield of 66% with an HPLC purity of 99% by area.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.